Recursion Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Recursion Pharmaceuticals Inc (RXRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.2% of the shares are freely tradable; institutional investors hold 68.8%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 9.38 | 50,304,691 | +16.5 | 06/30/2026 |
| ARK Investment Management LLC | 7.71 | 41,337,632 | +2.8 | 06/30/2026 |
| State Street Corp | 6.47 | 34,706,130 | +21.8 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 5.81 | 31,131,599 | +36.8 | 06/30/2026 |
| Baillie Gifford & Co Limited. | 4.38 | 23,487,907 | -0.8 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.25 | 22,765,940 | +2.3 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARK Innovation ETF | 4.29 | 23,028,792 | -7.3 | 09/30/2026 |
| Scottish Mortgage Ord | 3.39 | 18,174,384 | +0.0 | 07/31/2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.12 | 16,719,320 | -1.9 | 09/30/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.98 | 15,997,100 | +0.6 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Borgeson Blake | Director | 6,108,287 | 23,211,491 $ | Oct 6, 2026 | direct |
| Khan Najat | CEO and President | 2,072,890 | 7,876,982 $ | Sep 8, 2026 | direct |
| Li Dean Y | Director | 1,476,707 | 5,611,487 $ | Oct 1, 2026 | direct |
| Taylor Ben R | Chief Financial Officer | 1,071,462 | 4,071,556 $ | Sep 15, 2026 | direct |
| Hallett David | Chief Scientific Officer | 1,043,837 | 3,966,581 $ | Aug 17, 2026 | direct |
| Dar Zavain | Director | 245,371 | 932,410 $ | Oct 1, 2026 | direct |
| Hershberg Robert | Director | 162,156 | 616,193 $ | Oct 6, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 6, 2026 | Borgeson Blake | Director | Sell | 50,000 | 4.84 | 242,000 |
| Oct 6, 2026 | Hershberg Robert | Director | Sell | 25,000 | 5.00 | 125,000 |
| Oct 6, 2026 | Hershberg Robert | Director | Other | 25,000 | 2.22 | 55,500 |
| Oct 1, 2026 | Dar Zavain | Director | Other | 4,607 | 0.00 | – |
| Oct 1, 2026 | Li Dean Y | Director | Other | 3,378 | 0.00 | – |
| Sep 15, 2026 | Taylor Ben R | Chief Financial Officer | Other | 5,396 | 3.41 | 18,400 |
| Sep 8, 2026 | Khan Najat | CEO and President | Sell | 22,408 | 3.52 | 78,822 |
| Sep 1, 2026 | Borgeson Blake | Director | Sell | 30,000 | 3.34 | 100,200 |
| Aug 17, 2026 | Khan Najat | CEO and President | Other | 80,498 | 3.16 | 254,374 |
| Aug 17, 2026 | Hallett David | Chief Scientific Officer | Other | 26,657 | 3.16 | 84,236 |
| Aug 17, 2026 | Taylor Ben R | Chief Financial Officer | Other | 25,018 | 3.16 | 79,057 |
| Aug 4, 2026 | Borgeson Blake | Director | Sell | 30,000 | 3.25 | 97,500 |
| Jul 7, 2026 | Borgeson Blake | Director | Sell | 40,000 | 3.96 | 158,500 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.